In-depth review of cardiopulmonary support in COVID-19 patients with heart failure
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved..
Coronavirus disease 2019 infection has spread worldwide and causing massive burden to our healthcare system. Recent studies show multiorgan involvement during infection, with direct insult to the heart. Worsening of the heart function serves as a predictor of an adverse outcome. This finding raises a particular concern in high risk population, such as those with history of preexisting heart failure with or without implantable device. Lower baseline and different clinical characteristic might raise some challenge in managing either exacerbation or new onset heart failure that might occur as a consequence of the infection. A close look of the inflammatory markers gives an invaluable clue in managing this condition. Rapid deterioration might occur anytime in this setting and the need of cardiopulmonary support seems inevitable. However, the use of cardiopulmonary support in this patient is not without risk. Severe inflammatory response triggered by the infection in combination with the preexisting condition of the worsening heart and implantable device might cause a hypercoagulability state that should not be overlooked. Moreover, careful selection and consideration have to be met before selecting cardiopulmonary support as a last resort due to limited resource and personnel. By knowing the nature of the disease, the interaction between the inflammatory response and different baseline profile in heart failure patient might help clinician to salvage and preserve the remaining function of the heart.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
World journal of cardiology - 13(2021), 8 vom: 26. Aug., Seite 298-308 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Raffaello, Wilson Matthew [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 01.10.2021 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4330/wjc.v13.i8.298 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331306360 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331306360 | ||
| 003 | DE-627 | ||
| 005 | 20231225213155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4330/wjc.v13.i8.298 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331306360 | ||
| 035 | |a (NLM)34589166 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Raffaello, Wilson Matthew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In-depth review of cardiopulmonary support in COVID-19 patients with heart failure |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a Coronavirus disease 2019 infection has spread worldwide and causing massive burden to our healthcare system. Recent studies show multiorgan involvement during infection, with direct insult to the heart. Worsening of the heart function serves as a predictor of an adverse outcome. This finding raises a particular concern in high risk population, such as those with history of preexisting heart failure with or without implantable device. Lower baseline and different clinical characteristic might raise some challenge in managing either exacerbation or new onset heart failure that might occur as a consequence of the infection. A close look of the inflammatory markers gives an invaluable clue in managing this condition. Rapid deterioration might occur anytime in this setting and the need of cardiopulmonary support seems inevitable. However, the use of cardiopulmonary support in this patient is not without risk. Severe inflammatory response triggered by the infection in combination with the preexisting condition of the worsening heart and implantable device might cause a hypercoagulability state that should not be overlooked. Moreover, careful selection and consideration have to be met before selecting cardiopulmonary support as a last resort due to limited resource and personnel. By knowing the nature of the disease, the interaction between the inflammatory response and different baseline profile in heart failure patient might help clinician to salvage and preserve the remaining function of the heart | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cardiopulmonary support | |
| 650 | 4 | |a Coagulopathy | |
| 650 | 4 | |a Extracorporeal membranous oxygenation | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Ventricular assist device | |
| 700 | 1 | |a Huang, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Budi Siswanto, Bambang |e verfasserin |4 aut | |
| 700 | 1 | |a Pranata, Raymond |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of cardiology |d 2009 |g 13(2021), 8 vom: 26. Aug., Seite 298-308 |w (DE-627)NLM201987775 |x 1949-8462 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:8 |g day:26 |g month:08 |g pages:298-308 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4330/wjc.v13.i8.298 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 8 |b 26 |c 08 |h 298-308 | ||